Navigation Links
Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
Date:1/30/2008

LAVAL, QC, Jan. 30 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Mr. Gary Schmid will join Neurochem, effective February 4, 2008, and will serve as Chief Executive Officer (CEO) of the new business Neurochem has announced it is creating to develop and market nutraceuticals. Mr. Schmid joins the Company from Sante Naturelle A.G. Limited, the international manufacturers and marketers of Quebec's market-leading Adrien Gagnon natural health brands. Mr. Schmid joined Sante Naturelle in May 2006 as Chief Operating Officer and was appointed President and CEO later that year. In addition, Mr. Schmid spent 20 years at Abbott Laboratories Ltd. in a variety of positions of ever-increasing responsibility in sales and marketing where, in 2005, he was appointed General Manager, Abbott Nutrition.

"We are excited to welcome Mr. Schmid who will lead the team responsible for the commercialization of our first nutraceutical product, homotaurine, developed to enhance memory and cognition. The launch of homotaurine is planned in Canada in the near future, with subsequent commercial activities in other territories expected soon thereafter," said Dr. Francesco Bellini, Chairman, President and Chief Executive Officer of Neurochem. "Mr. Schmid's long track record and world-class marketing credentials will help create a unique, branded nutraceutical product company," he concluded.

As President and CEO of Sante Naturelle A.G., Mr. Schmid succeeded in developing and implementing that company's strategies to support future growth expectations, which translated into significantly increasing sales in domestic and export business segments and in the launch of 35 new products within 12 months.

Before joining Sante Naturelle, Mr. Schmid held positions with Abbott Laboratories Ltd. (Canada), where he served between 1985 and 2006, initially as a financial analyst with what was to become Abbott's nutrition division, and then rapidly moved into sales and marketing. Following a two-year assignment with Abbott International Ltd. in Chicago, Mr. Schmid returned to Canada in 1994 as National Sales Manager of the future nutrition division, progressed to a series of more responsible positions in marketing, including Marketing Director of Abbott's Pharma Division, before being appointed General Manager, Abbott Nutrition, in 2005. Mr. Schmid is a Commerce graduate of McGill University.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to patients suffering from serious diseases.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

For Further Information, please contact:

Lise Hebert, PhD (450) 680-4572

Vice President, Corporate Communications lhebert@neurochem.com

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for third quarter of fiscal 2007
2. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
3. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem to present at JPMorgan Healthcare Conference
6. WorldHeart Appoints David Pellone Chief Financial Officer
7. Novo Nordisk Appoints New Leader of North American Business
8. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
9. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
10. Resonant Medical Appoints New Vice President of Global Sales
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... The Radiology Business Management Association will select the 2017 ... Building Better Radiology Marketing Programs conference, held this year from March 5 ... awards are given out in five categories. They are:, ,     Patient ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Los Angeles-based ... episodes of WE TV’s “Mama June: From Not to Hot,” which will begin airing ... “Mama” June Shannon, known to millions from the 2012 reality television series, “Here Comes ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, ... Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist by ... directory that recognizes local physicians and dentists who have earned high ratings and superior ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... leading the discovery and development of innovative medicines targeting ... full year 2016 financial results on Thursday, March 2, ... host a conference call and webcast on March 2, ... quarter and full year 2016 financial results and provide ...
(Date:2/23/2017)... ... Research and Markets has announced the addition of the "Global ... report to their offering. The Global Antifungal Drugs Market ... next decade to reach approximately $12.8 billion by 2025. ... the given segments on global as well as regional levels presented in ...
(Date:2/23/2017)... Ga., Feb. 23, 2017  MiMedx Group, Inc. (NASDAQ: ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, ... and full year ended December 31, 2016. ... Revenue is a 31% increase over full year 2015 ...
Breaking Medicine Technology: